ker-050
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 15, 2020 (NCT04419649)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314737 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06499285 | Phase 3 | Dec 31, 2024 | Keros Therapeutics, PSI CRO |
| NCT05037760 | Phase 2 | Sep 10, 2021 | IQVIA, Keros Therapeutics |
| NCT04419649 | Phase 2 | Sep 15, 2020 | Keros Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Keros Therapeutics | For profit | 3 | 3 | 2 | 2020 |
| IQVIA | For profit | 1 | 0 | 1 | 2021 |
| PSI CRO | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1